Estimated heterogeneity across hormone receptor subtypes, excluding triple-negative breast cancer, was 0%, which indicates that the absence of a causal effect on this specific subtype [OR = 1.01 (95% CI, 0.98–1.04)] explains the observed heterogeneity across all five subtypes. Here, NR4A1 is linked to triple-negative breast carcinoma.